2 completed, 2 recruiting, 1 not yet recruiting. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Acepodia Biotech, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs ACE723 - Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic | Phase 1 | Not yet recruiting | Acepodia Biotech, Inc. | 70 | 2026-11-01 | 2026-10-06 |
| Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease ACE1831, Lymphodepleting chemotherapy - IgG4 Related Disease | Phase 1 / Phase 2 | Recruiting | Acepodia Biotech, Inc. | 34 | 2026-01-01 | 2026-10-02 |
| ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) Cyclophosphamide, Fludarabine, ACE2016 - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Recruiting | Acepodia Biotech, Inc. | 30 | 2024-08-22 | 2025-07-01 |
| ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies Cyclophosphamide, Fludarabine, ACE1831 - B-cell Lymphoma, Non Hodgkin Lymphoma | Phase 1 | Completed | Acepodia Biotech, Inc. | 16 | 2023-01-21 | 2026-06-30 |
| ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors ACE1702, Cyclophosphamide, Fludarabine - Locally Advanced Solid Tumor, Metastatic Cancer | Phase 1 | Completed | Acepodia Biotech, Inc. | 12 | 2020-06-24 | 2024-12-05 |
Neoplasm Metastasis (2) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Immunoglobulin G4-Related Disease (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Non-Hodgkin (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
Cyclophosphamide (3) · fludarabine (3) · obinutuzumab (1) · pembrolizumab (1)
United States (4) · Taiwan (3) · China (2) · Hong Kong (1) · Japan (1)